To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Eli Lilly and Co. is suing an Indianapolis-based weight-loss clinic it says is improperly selling Lilly’s hugely popular ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...